Histopathology and Lo-multiplex immunofluorescence dataset of cell‐cycle related proteins in renal cell carcinoma – SORCE trial

This dataset corresponds to 443 clear-cell and 37 papillary renal cell carcinoma (RCC) cohort of patients from the UK translational arm of the SORCE trial, a phase III randomized study evaluating adjuvant sorafenib versus placebo in renal cancer (ClinicalTrials.gov identifier: NCT00492258). This multi-center cohort encompasses intermediate- and high-risk RCC cases randomized to receive sorafenib adjuvant therapy (1 or 3 years) or placebo. The image collection comprises tumour samples from 480 patients enrolled in the trial’s UK tissue biobank as part of TRANSORCE. For each patient, a formalin-fixed, paraffin-embedded (FFPE) primary tumor section was used to generate a whole-slide haematoxylin and eosin (H&E) image, and lo-multiplex immunofluorescence (mIF) imaging was performed for 382 cases.
The mIF panel included p21^CDKN1a, MCM2, and CD105 (endoglin), together with Hoechst nuclear counterstaining. All H&E whole-slide images (WSIs) were acquired using a Zeiss Axio Scan.Z1 scanner at 40× magnification, and mIF images were acquired on the same platform at 20× magnification. Both image types are provided in CZI format. Automated image analysis was performed on all mIF slides using HALO® software. The principal derived metric for each tumour is the percentage of p21⁺/MCM2⁻ and CD105⁺/p21⁺/MCM2⁻ cells, representing the cell-cycle arrest fraction in tumor and endothelial cells. In total, the dataset includes 480 H&E WSIs and 382 multi-channel mIF WSIs. Also, the dataset includes two CSV files containing quantitative metrics (phenotypic proportions and average nuclear/cell parameters), along with a clinical metadata file providing de-identified patient information. The clinical dataset accompanying this cohort includes the following variables: treatment arm ( A: placebo, B: one year sorafenib, C: three year sorafenib), age at randomization, time from diagnosis to randomization, date of randomization, date of operation, gender, WHO performance status, histology at diagnosis, pathological T stage, regional lymph node status, tumor size, ISUP nuclear grade, presence of tumor necrosis, raw Leibovich score, Leibovich risk group, maximum tumor diameter, disease-free survival status (DFS 0/1) and date, and overall survival status (OS 0/1) and date. All data are released under a CC0 license, enabling unrestricted reuse by the research community.